Pradosh Kumar Sarangi

Health-Related Quality of Life and Cost-Effectiveness of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Monotherapy in Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Systematic Review

First-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have transformed the management of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Although randomized trials have demonstrated improvements in clinical outcomes, treatment decisions incr...